Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome.


Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 28 11 2018
medline: 27 8 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

Precise genetic counseling and prenatal diagnosis are often hindered by incomplete penetrance of risk variance and complex patterns of inheritance. Here, we performed a clinical and genetic study of a five-generation Pakistani family with a history of multiple cases of childhood brain tumors. Six affected individuals died of brain tumors at very early ages and three were confirmed as having a homozygous mutation in exon 6 of the PMS2 gene (c.543delT). Fifteen members of the family were identified as heterozygous carriers of this mutation with a lack of cancer incidence. Both clinical manifestations and genetic test results of brain tumor patients in the family support the diagnosis of constitutional mismatch repair deficiency (CMMRD) syndrome, a condition in which individuals carry homozygous germline mutations in mismatch repair machinery genes with an early onset of malignancies such as glioma. This information was used to guide prenatal diagnosis with genetic testing on chorionic villus samples for the family. This is the first report of prenatal genetic diagnosis of hereditary brain tumor.

Identifiants

pubmed: 30478739
doi: 10.1007/s10689-018-0112-4
pii: 10.1007/s10689-018-0112-4
doi:

Substances chimiques

PMS2 protein, human EC 3.6.1.-
Mismatch Repair Endonuclease PMS2 EC 3.6.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

261-265

Références

World J Gastroenterol. 2015 Aug 21;21(31):9253-61
pubmed: 26309352
J Med Genet. 2014 Jun;51(6):355-65
pubmed: 24737826
J Natl Cancer Inst. 2006 Mar 1;98(5):358-61
pubmed: 16507833
BMC Med Genet. 2017 Apr 5;18(1):40
pubmed: 28381238
J Biosoc Sci. 2019 May;51(3):418-435
pubmed: 30289091
Science. 2006 Oct 13;314(5797):268-74
pubmed: 16959974
Int J Cancer. 2016 Jan 15;138(2):380-5
pubmed: 26293621
Hum Mutat. 2006 May;27(5):490-5
pubmed: 16619239
Am J Hum Genet. 2004 May;74(5):954-64
pubmed: 15077197
Nat Rev Genet. 2002 Mar;3(3):225-9
pubmed: 11972160
Genet Med. 2016 Jan;18(1):13-9
pubmed: 25856668
Clin Cancer Res. 2017 Jun 1;23(11):e32-e37
pubmed: 28572265
J Med Genet. 2014 May;51(5):283-93
pubmed: 24556086
J Pathol. 2017 Nov;243(3):331-341
pubmed: 28805995
Genet Res (Camb). 2016 Nov 11;98:e15
pubmed: 27834155
J Med Genet. 2015 Nov;52(11):770-8
pubmed: 26318770
Future Oncol. 2012 Apr;8(4):441-50
pubmed: 22515447
Clin Genet. 2015 Jun;87(6):536-42
pubmed: 25318681
Clin Genet. 2018 Jul;94(1):61-69
pubmed: 29286535
Neuro Oncol. 2008 Feb;10(1):93-7
pubmed: 17993636
Clin Genet. 2001 Aug;60(2):89-98
pubmed: 11553039
Cancer Lett. 2007 May 8;249(2):148-56
pubmed: 17029773

Auteurs

Shahid Mahmood Baig (SM)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)-PIEAS, Faisalabad, 38000, Pakistan.

Ambrin Fatima (A)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)-PIEAS, Faisalabad, 38000, Pakistan.

Muhammad Tariq (M)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)-PIEAS, Faisalabad, 38000, Pakistan.

Tahir Naeem Khan (TN)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)-PIEAS, Faisalabad, 38000, Pakistan.

Zafar Ali (Z)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)-PIEAS, Faisalabad, 38000, Pakistan.

Mohammad Faheem (M)

Oncology Department, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), G-8/3, Islamabad, 44000, Pakistan.

Humera Mahmood (H)

Oncology Department, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), G-8/3, Islamabad, 44000, Pakistan.

Patrick Killela (P)

Department of Pathology, Duke University Medical Center, 199B-MSRB Building, Research Drive, DUMC-3156, Durham, NC, 27710, USA.

Matthew Waitkus (M)

Department of Pathology, Duke University Medical Center, 199B-MSRB Building, Research Drive, DUMC-3156, Durham, NC, 27710, USA.

Yiping He (Y)

Department of Pathology, Duke University Medical Center, 199B-MSRB Building, Research Drive, DUMC-3156, Durham, NC, 27710, USA.

Fangping Zhao (F)

Genetron Health (Beijing) Co. Ltd, Beijing, China.

Sizhen Wang (S)

Genetron Health (Beijing) Co. Ltd, Beijing, China.

Yuchen Jiao (Y)

Cancer Institute & Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Hai Yan (H)

Department of Pathology, Duke University Medical Center, 199B-MSRB Building, Research Drive, DUMC-3156, Durham, NC, 27710, USA. hai.yan@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH